Related references
Note: Only part of the references are listed.The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature
G. Saudemont et al.
BMC PALLIATIVE CARE (2020)
Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting A Randomized Pilot Trial
Rudolph M. Navari et al.
JAMA ONCOLOGY (2020)
Advance Directives/Care Planning: Clear, Simple, and Wrong
Keisuke Kaneishi et al.
JOURNAL OF PALLIATIVE MEDICINE (2020)
Safety and effectiveness of antipsychotic medication for delirium in patients with advanced cancer: A large-scale multicenter prospective observational study in real-world palliative care settings
Isseki Maeda et al.
GENERAL HOSPITAL PSYCHIATRY (2020)
Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study
Signe Harder et al.
SUPPORTIVE CARE IN CANCER (2019)
The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment
Signe Harder et al.
SUPPORTIVE CARE IN CANCER (2019)
2016 Updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer
Declan Walsh et al.
SUPPORTIVE CARE IN CANCER (2017)
Patient-reported outcomes in cancer care - hearing the patient voice at greater volume
Thomas W. LeBlanc et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Olanzapine in the Management of Difficult to Control Nausea and Vomiting in a Palliative Care Population: A Case Series
David MacKintosh
JOURNAL OF PALLIATIVE MEDICINE (2016)
Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy
Srinivas Raman et al.
QUALITY OF LIFE RESEARCH (2016)
Use of olanzapine for the relief of nausea and vomiting in patients with advanced cancer: a multicenter survey in Japan
Keisuke Kaneishi et al.
SUPPORTIVE CARE IN CANCER (2016)
A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients
C. Fonte et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Olanzapine: Palliative Medicine Update
Eric Prommer
AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE (2013)
Minimal Clinically Important Differences in the Edmonton Symptom Assessment System in Patients With Advanced Cancer
Gillian Bedard et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2013)
Olanzapine for the Relief of Nausea in Patients With Advanced Cancer and Incomplete Bowel Obstruction
Keisuke Kaneishi et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2012)
A Comparison of Change in the 0-10 Numeric Rating Scale to a Pain Relief Scale and Global Medication Performance Scale in a Short-term Clinical Trial of Breakthrough Pain Intensity
John T. Farrar et al.
ANESTHESIOLOGY (2010)
BASELINE OBSERVATION CARRY FORWARD: REASONING, PROPERTIES, AND PRACTICAL ISSUES
Jun Shao et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2009)
Understanding the minimum clinically important difference: a review of concepts and methods
Anne G. Copay et al.
SPINE JOURNAL (2007)
An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer
J Stephenson et al.
SUPPORTIVE CARE IN CANCER (2006)
A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain
SD Passik et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2002)
Defining the clinically important difference in pain outcome measures
JT Farrar et al.
PAIN (2000)
Share Paper
